Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFN-11 (Sumatriptan) 3 mg vs 6 mg for Rapidly Escalating Migraine
NCT02571049Phase 2Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Sep 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sumatriptan in migraine (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Percentage of Subjects Reporting Pain Freedom at 60 Minutes Post-treatment. Started Sep 2015; status: completed.
02
Drugs
sumatriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02571049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571049.